Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

78.27 +1.13 (+1.46%)
Official Closing Price Updated: 4:10 PM EDT, Jun 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Recent Filing Shows That Rep. Josh Gottheimer Sold Over $54K Worth of Merck & Co Stock
Via Benzinga
Merck Stock Heads For 5th Day Of Losses As TD Cowen Downgrades On Gardasil Woes, But Retail Holds Strong
The HPV vaccine had been a key growth driver in China until last year when economic headwinds disrupted demand. 
Via Stocktwits
Merck: 4 No-Brainer Reasons to Buy This Dip
Merck & Co. stock was pummeled by 10% after its earnings release on soft forecasts, but the overreaction by the market may present a buying opportunity. 
Via MarketBeat
Better High-Yield Dividend Stock: Pfizer vs. Merck
Via The Motley Fool
Market Whales and Their Recent Bets on MRK Options
Via Benzinga
Top 3 Health Care Stocks You'll Regret Missing This Month
Via Benzinga
Why Merck Stock Is Plummeting Today
Via The Motley Fool
Market Whales and Their Recent Bets on MRK Options
Via Benzinga
Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
From Merck & Co., Inc.
Via Business Wire
Analysts Defend Merck Amid Investor Concerns Over Weak Guidance
Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a lower-than-expected 2025 outlook. 
Via Benzinga
Uncover the latest developments among S&P500 stocks in today's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Merck (MRK) Q4 2024 Earnings Call Transcript
MRK earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Looking for the most active stocks in the S&P500 index on Tuesday?
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Tuesday and discover the stocks that are dominating the trading activity and setting the pace for... 
Via Chartmill
Merck Retail Traders See Buying Opportunity As Stock Dives Toward Worst Day in 17 Years On Weak Guidance
Gardasil, its HPV vaccine, posted a 17% decline in sales to $1.55 billion, primarily due to lower demand in China. 
Via Stocktwits
Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below.
Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Tuesday. Stay informed about the market activity below. 
Via Chartmill
Discover which S&P500 stocks are making waves on Tuesday.
Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session. 
Via Chartmill
US Stocks Rise Despite China's Trade Fears, Palantir Defies Gravity, Gold Rallies Further: What's Driving Markets Tuesday?
U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the world’s two largest economies. 
Via Benzinga
Why Merck (MRK) Stock Is Falling Today
Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by a... 
Via StockStory
Gapping S&P500 stocks in Tuesday's session
Curious about the market action on Tuesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
Get insights into the top movers in the S&P500 index of Tuesday's pre-market session.
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements. 
Via Chartmill
Merck Tops Q4 Earnings And Revenue Estimates
Merck came out with quarterly earnings of $1.72 per share. 
Via Talk Markets
Topics Stocks / Equities
Merck's Gardasil Vaccine Slowdown In China Bites Again, Stock Falls On Weak 2025 Outlook
Merck posted Q4 sales of $15.62 billion, driven by Keytruda's 19% growth. FY25 guidance lags estimates, citing Gardasil shipment pause in China and forex impact. 
Via Benzinga
PayPal, Estée Lauder, UBS And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Merck’s (NYSE:MRK) Q4 Sales Top Estimates But Stock Drops
Global pharmaceutical company Merck (NYSE:MRK) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 6.8% year on year to $15.62 billion. On the other hand, the company’s... 
Via StockStory
Merck Tops Q4 Forecasts, But Dow Jones Giant Dives On 2025 Guidance
Merck topped Wall Street's Q4 expectations Tuesday, but the stock is taking a hit on light guidance. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results
From Merck & Co., Inc.
Via Business Wire
Earnings Scheduled For February 4, 2025
Via Benzinga
Merck Vs. Pfizer: Which Pharmaceutical Giant Will Prevail In Q4 Earnings?
Merck and Pfizer are heading into fourth quarter earnings with different technical setups, leaving investors unsure of which stock will prevail. While Merck shows short-term strength, Pfizer is... 
Via Benzinga
The Dogs Of The Dow 2025
The Dogs of the Dow is an investing strategy well-known to retail and institutional investors. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts could pose risks for companies with significant drug exposure. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.